https://pittplusme.org/study/1238
Type 2 Diabetes Study
STUDY BASICS
Have you been newly diagnosed with diabetes and are age 55-85? Have you been prescribed metformin, but have not yet started taking it? If so, you may be able to participate in a research study to help learn more about metformin’s effects on the body. Compensation provided.
STUDY PURPOSE
People who are newly diagnosed with type 2 diabetes—a condition that affects the body’s ability to process glucose (sugar)—are often prescribed a drug called metformin to improve blood sugar control. Recent research suggests that metformin may also help decrease inflammation and enhance the body’s immune response. The purpose of this study is to help researchers learn more about metformin’s effects on the body. Researchers hope their findings will lead to better treatments for people with diabetes and other diseases in the future.
COULD THIS STUDY BE RIGHT FOR YOU?
- Ages 55-85
- UPMC patient
- Newly diagnosed with type 2 diabetes
- Received a prescription for metformin, but have not yet started taking it
WHAT PARTICIPANTS CAN EXPECT
Participation includes two in-person visits and two phone calls. Participants will complete questionnaires and provide two blood samples. One blood sample will be collected before starting metformin and one will be collected two weeks after starting metformin.
IRB: STUDY19070161
- A Pilot Study: Metformin as an immune and inflammatory modulating therapy in older adults with newly diagnosed type two diabetes
MEET THE RESEARCHER
Brian Zuckerbraun
Brian S. Zuckerbraun, MD, FACS, is Professor of Surgery and Chief of the Division of General/Trauma and Acute Care Surgery at the University of Pittsburgh. A graduate of Northwestern University, Dr. Zuckerbraun’s research interests include the protective responses within the liver that limit injury response to hemorrhage and sepsis as well as vascular injury and pulmonary arterial hypertension.